<?xml version="1.0" encoding="UTF-8"?>
<p>At present, there is no single specific anti-viral therapy available against COVID, and the treatment is mostly supportive. The cases of 2019 nCoV (SARS-CoV-2) infection have been continuously increasing throughout the world ever since its outbreak in China. Currently, SARS-CoV-2 M protein has been used as a target, which may be inhibited by the already available and approved drugs. For this reason, the safety profile of these FDA-approved drugs is carefully documented and the efficacy of the selected few can be quickly examined against the novel virus (drug repurposing). Previous studies have demonstrated the efficacy of the available drugs against SARS-CoV-2 “P” and “L” proteins and their potential to inhibit the catalytic area and inactivate the virus [
 <xref rid="REF11" ref-type="bibr">11</xref>,
 <xref rid="REF14" ref-type="bibr">14</xref>].
</p>
